A Randomized, Monocentric, Double-blind, Multiple Daily Dose, Two-period, 14 Day Cross-over Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog U-100 in Patients With Type 1 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2016
At a glance
- Drugs Insulin lispro (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Adocia
- 15 Mar 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
- 14 Mar 2016 Top-line results published in Adocia and Lilly media release.
- 25 Aug 2015 New trial record